According to LaKE Pharma's announcement, the company recently completed a 24-week monotherapy study of LAE102 in the low-dose cohort, with consistent results from prior single-ascending-dose (SAD) and multiple-ascending-dose (MAD) studies. The low-dose group showed encouraging weight loss effects with observed increases in muscle mass and decreases in fat mass, while demonstrating good tolerability with no serious adverse events reported, and no cases of diarrhea, muscle cramps, or acne.
The high-concentration formulation of LAE102 is now ready, and the company has completed patient enrollment for the high-dose cohort to further evaluate efficacy and safety over the 24-week treatment period.